Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma - PubMed (original) (raw)

doi: 10.1186/1476-4598-7-75.

Neville J De Young, Sandra J Pavey, Nicholas K Hayward, Derek J Nancarrow, David C Whiteman, B Mark Smithers, Andrew R Ruszkiewicz, Andrew D Clouston, David C Gotley, Peter G Devitt, Glyn G Jamieson, Paul A Drew

Affiliations

Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma

Eric Smith et al. Mol Cancer. 2008.

Abstract

Background: Barrett's esophagus (BE) is the metaplastic replacement of squamous with columnar epithelium in the esophagus, as a result of reflux. It is the major risk factor for the development of esophageal adenocarcinoma (EAC). Methylation of CpG dinucleotides of normally unmethylated genes is associated with silencing of their expression, and is common in EAC. This study was designed to determine at what stage, in the progression from BE to EAC, methylation of key genes occurs.

Results: We examined nine genes (APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3, and TMEFF2), frequently methylated in multiple cancer types, in a panel of squamous (19 biopsies from patients without BE or EAC, 16 from patients with BE, 21 from patients with EAC), BE (40 metaplastic, seven high grade dysplastic) and 37 EAC tissues. The methylation frequency, the percentage of samples that had any extent of methylation, for each of the nine genes in the EAC (95%, 59%, 76%, 57%, 70%, 73%, 95%, 74% and 83% respectively) was significantly higher than in any of the squamous groups. The methylation frequency for each of the nine genes in the metaplastic BE (95%, 28%, 78%, 48%, 58%, 48%, 93%, 88% and 75% respectively) was significantly higher than in the squamous samples except for CDKN2A and RBP1. The methylation frequency did not differ between BE and EAC samples, except for CDKN2A and RUNX3 which were significantly higher in EAC. The methylation extent was an estimate of both the number of methylated alleles and the density of methylation on these alleles. This was significantly greater in EAC than in metaplastic BE for all genes except APC, MGMT and TIMP3. There was no significant difference in methylation extent for any gene between high grade dysplastic BE and EAC.

Conclusion: We found significant methylation in metaplastic BE, which for seven of the nine genes studied did not differ in frequency from that found in EAC. This is also the first report of gene silencing by methylation of ID4 in BE or EAC. This study suggests that metaplastic BE is a highly abnormal tissue, more similar to cancer tissue than to normal epithelium.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Methylation and expression of APC, CDKN2A, ID4, MGMT, RBP1, RUNX3, SFRP1, TIMP3 and TMEFF2 in esophageal cancer cell lines OE33 and TE7. The esophageal cancer cell lines OE33 and TE7 were treated with either 1 μmol/L aza-dC or vehicle for 72 hours. The medium was replaced with fresh medium only, and the cells incubated for a further 24 hours before harvesting. Bisulphite modified DNA was amplified using primers and PCR conditions (Table 2) which were specific for bisulphite modified DNA, did not discriminate between methylated and unmethylated sequences, and did not amplify unmodified DNA. The PCR products were melted by increasing the temperature from 60 to 95°C, rising 0.5 or 1°C at each step, waiting 30 seconds on the first step then 5 seconds for each step thereafter. Data was collected and analysed using the Melt Curve Analysis function of the RG-3000 Application Software. The left hand column shows the melt curves for each of the nine genes for OE33, the central column for TE7. Each plot shows the melt curves for the unmethylated (black lines) and methylated (open circles) controls and the cell lines treated with vehicle (red circles) or aza-dC (green circles). The horizontal axis represents temperature and the vertical axis -dF/dT. CDKN2A was not amplified in TE7. Interpretation of the melt curves is described in the Materials and Methods. The right hand column shows the gene expression in cell lines treated with vehicle (red columns) or aza-dC (green columns), as determined by qRT-PCR and normalised to HMBS. Data shown are the means ± SD from three independent experiments. TMEFF2 expression was below detectable limits in either cell line treated with vehicle or aza-dC.

Figure 2

Figure 2

Methylation frequency and methylation extent in esophageal tissues. Methylation of each gene was measured in multiple biopsies of squamous mucosa (S, n = 19) from seven patients without BE, single biopsies of squamous mucosa (S-BE, n = 16) and multiple biopsies of columnar mucosa (BE, n = 40) from 18 patients with BE, single biopsies of squamous mucosa (S-EAC, n = 21), high grade dysplastic Barrett's (D-EAC, n = 7) and tumor (EAC, n = 37) from 38 patients with EAC. The methylation was graded as unmethylated (white), methylated 1 (yellow), 2 (red), or 3 (blue), as described in the Materials and Methods.

Figure 3

Figure 3

Number of methylated genes in esophageal tissues. The number of methylated genes in specimens of squamous mucosa from patients without BE (S), squamous mucosa (S-BE) and columnar mucosa (BE) from patients with BE, and squamous mucosa (S-EAC), high grade dysplastic Barrett's (D-EAC) and adenocarcinoma (EAC) from 38 patients with EAC.

Figure 4

Figure 4

Expression and methylation in esophageal tissues. (a) Normalised mRNA expression of ID4, MGMT, RBP1, and SFRP1 in squamous (S-EAC), high grade dysplastic Barrett's (D-EAC) or tumor (EAC) tissues from patients with EAC. (b) Normalised expression of ID4, MGMT, and RBP1 in tumors unmethylated or methylated for the gene. The horizontal bar represents the median expression.

References

    1. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119:333–338. doi: 10.1053/gast.2000.9302. - DOI - PubMed
    1. Murray L, Watson P, Johnston B, Sloan J, Mainie IM, Gavin A. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ. 2003;327:534–535. doi: 10.1136/bmj.327.7414.534. - DOI - PMC - PubMed
    1. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67. doi: 10.1371/journal.pmed.0040067. - DOI - PMC - PubMed
    1. Keswani RN, Noffsinger A, Waxman I, Bissonnette M. Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2006;15:1243–1249. doi: 10.1158/1055-9965.EPI-06-0010. - DOI - PubMed
    1. Tannapfel A. Molecular findings in Barrett's epithelium. Dig Dis. 2004;22:126–133. doi: 10.1159/000080311. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources